mammaprint.co.uk Report : Visit Site


  • Server:Sucuri/Cloudproxy...

    The main IP address: 213.19.176.48,Your server Netherlands,Amsterdam ISP:The People's Valley  TLD:uk CountryCode:NL

    The description :') international publications ordering & client login careers     toggle navigation -- healthcare professionals breast cancer mammaprint blueprint kit (miseq®) the mindact trial online custome...

    This report updates in 12-Jun-2018

Technical data of the mammaprint.co.uk


Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host mammaprint.co.uk. Currently, hosted in Netherlands and its service provider is The People's Valley .

Latitude: 52.374031066895
Longitude: 4.8896899223328
Country: Netherlands (NL)
City: Amsterdam
Region: Noord-Holland
ISP: The People's Valley

the related websites

    forum.tnbcfoundation.org ecancer.org dutchnews.nl cogseu.org hindawi.com pathways.nice.org.uk 

HTTP Header Analysis


HTTP Header information is a part of HTTP protocol that a user's browser sends to called Sucuri/Cloudproxy containing the details of what the browser wants and will accept back from the web server.

X-XSS-Protection:1; mode=block
X-Content-Type-Options:nosniff
Transfer-Encoding:chunked
Set-Cookie:X-Mapping-dbfpeoop=288420681D764946F07AD21A1D478AD3; path=/
Server:Sucuri/Cloudproxy
Connection:keep-alive
Link:; rel="https://api.w.org/", ; rel=shortlink
X-Sucuri-Cache:MISS
Date:Tue, 12 Jun 2018 09:20:36 GMT
X-Frame-Options:SAMEORIGIN
X-Sucuri-ID:14006
Content-Type:text/html; charset=UTF-8

DNS

soa:ns1.thepeoplesvalley.net. hostmaster.thevalley.nl. 2016040501 28800 7200 604800 86400
ns:ns2.thepeoplesvalley.net.
ns1.thepeoplesvalley.net.
mx:MX preference = 10, mail exchanger = mx3.sara.nl.
MX preference = 5, mail exchanger = mx2.sara.nl.
ipv4:IP:213.19.176.48
ASN:3356
OWNER:LEVEL3 - Level 3 Parent, LLC, US
Country:GB
ipv6:2001:4c08:2001:45::48//10753//LVLT-10753 - Level 3 Parent, LLC, US//GB

HtmlToText

') international publications ordering & client login careers     toggle navigation -- healthcare professionals breast cancer mammaprint blueprint kit (miseq®) the mindact trial online customer portal our science publications managed care educational presentations patients breast cancer about company overview leadership board of directors medical advisory board clinical advisory panel milestones awards & recognition our science accreditations & licenses investors & press news and press releases collaborations 2017 event calendar contact us search for: search more breast cancer agendia > breast cancer the agendia breast cancer test suite home clinical studies frequently asked questions insurance coverage uncover more. the biology of your breast cancer is unique. identifying the most effective, tailored therapies for your tumor is called personalized medicine , which starts with precision science — which is what we do at agendia. traditionally, physicians have relied only on clinical-pathological factors such as age, tumor size, tumor grade, lymph node involvement, and hormone receptor status to make breast cancer treatment decisions. while this information is important and still used, the agendia breast cancer test suite uncovers your hidden breast cancer biology, providing you and your physician more information to help determine the most appropriate treatment management decisions for your specific tumor. please see the descriptions below to learn more about the agendia breast cancer test suite. mammaprint. answers, not ambiguity mammaprint ® 70-gene breast cancer recurrence test mammaprint is currently the only breast cancer recurrence test backed by peer-reviewed, prospective outcome data. unlike other genomic tests, your doctor is provided with a mammaprint low risk or high risk result, eliminating the uncertainty of an intermediate risk score which can affect up to 39% of patients tested. 3 a mammaprint low risk result means you have a 10%, or 1 in 10 chance of your cancer returning. a mammaprint high risk result means you have a 29%, or 3 out of 10 chance of it returning. 9 these results are based on a 10-year follow-up of a reference group of patients who had no additional treatment. these results, in addition to all other factors help you and your doctor make the most appropriate breast cancer treatment decisions. blueprint ® 80-gene molecular subtyping assay blueprint molecular subtyping provides deeper insight into tumor pathways, uncovering your hidden tumor biology. molecular subtyping informs your doctor about how the tumor is functioning underneath the surface. traditional subtyping (such as ihc or fish) assess a tumor by looking at cell surface characteristics, while molecular subtyping looks deeper at the functional level, to see which genes are really driving the tumor’s behavior. blueprint will determine if your breast cancer is luminal-type (a or b), basal-type, or her2-type. these findings are important when determining the treatments that are most appropriate for your specific tumor. low risk or high risk result: no intermediate category having easy-to-interpret information helps you and your doctor make the most appropriate treatment management decisions. mammaprint’s binary results removes the ambiguity you may get with other genomic tests, which have been shown to be as high as 39% of patients tested. 3 strong prognostic power, proven long-term a 25-year follow-up study to the original new england journal of medicine publication of mammaprint showed that these results have durable, accurate, long-term prognostic value. these results are the longest-term follow-up study of its kind. “this remarkable long-term study demonstrates the ability of the 70-gene signature to accurately differentiate higher-risk from lower-risk women with regard to risk of recurrence and overall survival, at a time in their lives when breast cancer can have its most devastating impact on fertility, productivity, and capacity to fulfill child-rearing responsibilities,” mammaprint and blueprint are intended for prognostic use only. mammaprint result is not intended to determine the outcome of disease, not to suggest or infer an individual’s response to therapy. a mammaprint low risk result does not ensure that distant risk of recurrence will not recur. similarly, a high risk result does not ensure that distant risk of recurrence will occur. test results should be used in conjunction with other clinic-pathological factors and standard practice of medicine. in the u.s., mammaprint is an fda cleared test, performed in a central laboratory using gene expression profiles obtained from formalin-fixed paraffin embedded (ffpe) breast cancer tissue samples, to assess a patient’s risk for distant metastasis within 5 years. blueprint is a laboratory-developed test that was developed and is performed exclusively by agendia. in the eu, mammaprint and blueprint are ce marked tests, performed in a central laboratory, using gene expression profiles obtained from formalin-fixed paraffin embedded (ffpe) breast cancer tissue samples. what to ask your doctor ask your doctor to run the agendia breast cancer test suite on your breast cancer. these tests can be run on a sample of your tumor that was removed during biopsy or surgery and was embedded in paraffin for storage (ffpe tissue). no new biopsy or surgical tissue sample is usually required. if your doctor is unfamiliar with agendia testing, please call customer care at 888-321-2732, and we can help connect them with a local agendia oncology specialist. cleared by the fda with fda clearance, have confidence in your results 8 mammaprint received fda clearance in 2007 and was the first in vitro diagnostic multivariate index assay (ivdmia) to be cleared by the regulatory agency. an ivdmia is a device that combines the values of multiple variables using an interpretative function (bioinformatics algorithm) to provide a single, patient specific result, that is intended for use in the diagnosis of disease and which provides a result whose derivation is non-transparent, and for that reason, cannot be independently derived or verified by the end user. mammaprint’s fda clearance confers confidence in its safety and effectiveness, ensuring that the peer reviewed, published studies used in its development, validation and ivdmia clearance have been evaluated by the united states food and drug administration. the fda label indicates that as a diagnostic tool, mammaprint has a 98.9% degree of accuracy in classifying patients as low risk or high risk and technical reproducibility of 98.5%. mammaprint’s fda indication – patient eligibility in the usa breast cancer recurrence and/or metastasis is partly dependent on the activation and suppression of certain genes located within the primary breast tumor. the fda cleared mammaprint profile is a ffpe tissue based genomics test which uses the latest microarray technology to analyze a patient’s breast tumor biology to predict whether existing cancer has the ability to metastasize. this 70-gene profile is validated as an independent indicator for breast cancer prognosis for women with lymph node-negative, estrogen receptor positive breast cancer and estrogen receptor negative disease. ask your doctor if the mammaprint test is right for you. interpreting your test results agendia provides a summary page designed for patients to help understand their individual results and have a meaningful discussion with their doctor about treatment options. these results, combined with all other factors help you and your doctor make the most appropriate, personalized treatment decisions. participate in a clinical registry current clinical registry trials agendia’s extensive clinical studies and research collaborations have produced numerous retrospective and prospective validation publications over the past decade. recently published studies further support the prognostic and predictive clinical utility of mammaprint for early stage breast cancer patients, and large, multi-institutional clinical trials, such as mindact and ispy-2 , can be expected to expand the assay’s clinical importance and indications for use. in the first ever phase iii, prospective, randomized study for a breast cancer recurrence assay, the five year results of the m icroarray i n n ode-negative (or 1-3 positive lymph node) d isease may a void c hemo t herapy (mindact) clinical trial showed 46% of clinically high risk patients were genomically low risk and showed no statistical benefit to chemotherapy. currently, agendia is enrolling institutions and cancer centers worldwide in the following studies for breast cancer: mint : the multi institutional neo adjuvant therapy mammaprint project trial (nct01501487) contact a customer care representative to learn more about participating in a clinical study. they can be reached at 888-321-2732 or by email at [email protected] download resources click on the links below to download helpful resource materials: patient information sheet patient brochure patient brochure (spanish) what is genomic testing? genomic tests look at your specific tumor’s genes, to help find out what’s driving its growth. using gene expression testing to help design a tailored treatment plan is called personalized medicine . these are not the same as genetic tests that determine your inherited risk or hereditary predisposition for cancer. your physician will assess many factors prior to determining your treatment plan, including the size of the tumor, lymph node involvement, and the hormone receptor status of your cancer. these factors, along with your tumor’s genomic profile , can help you and your physician make the most informed treatment decisions for your specific type of cancer. your tumor is unique , your treatment should be too faqs dealing with an "intermediate" breast cancer recurrence score breast cancer patient cari g. explains how mammaprint’s definitive results helped her and her physician choose the best course of treatment when she was initially given an ambiguous intermediate result from the 21-gene assay share this video     http://www.youtube.com/watch?v=hnj5u7ylndg dealing with an "intermediate" breast cancer recurrence score breast cancer patient cari g. explains how mammaprint’s definitive results helped her and her physician choose the best course of treatment when she was initially given an ambiguous intermediate result from the 21-gene assay share this video     http://www.youtube.com/watch?v=hnj5u7ylndg better breast cancer diagnosis with blueprint tv report on a patient’s journey to a better breast cancer diagnosis. dr. mark gittleman explains how new research with blueprint and mammaprint, which are molecular diagnostic tests, can refine and personalize a woman’s treatment for breast cancer. share this video     http://www.youtube.com/watch?v=u1qu9k2co-u better breast cancer diagnosis with blueprint tv report on a patient’s journey to a better breast cancer diagnosis. dr. mark gittleman explains how new research with blueprint and mammaprint, which are molecular diagnostic tests, can refine and personalize a woman’s treatment for breast cancer. share this video     http://www.youtube.com/watch?v=u1qu9k2co-u julieta julieta was originally told she needed chemotherapy but wanted to avoid it. share this video     http://www.youtube.com/watch?v=liphuiate94 julieta julieta was originally told she needed chemotherapy but wanted to avoid it. share this video     http://www.youtube.com/watch?v=liphuiate94 abc news see how the mammaprint results published from the raster study helped breast cancer patient jennifer p. confidently avoid chemotherapy share this video     http://www.youtube.com/watch?v=erqys71yygk abc news see how the mammaprint results published from the raster study helped breast cancer patient jennifer p. confidently avoid chemotherapy share this video     http://www.youtube.com/watch?v=erqys71yygk genomic testing for breast cancer patients dr. stephanie akbari, md, discusses how genomic testing is used to help guide treatment decisions for her patients share this video     http://www.youtube.com/watch?v=guxeweeqzz0 genomic testing for breast cancer patients dr. stephanie akbari, md, discusses how genomic testing is used to help guide treatment decisions for her patients share this video     http://www.youtube.com/watch?v=guxeweeqzz0 mary mary is confident knowing that she really needed chemotherapy. share this video     http://www.youtube.com/watch?v=5pr423z3sq4 mary mary is confident knowing that she really needed chemotherapy. share this video     http://www.youtube.com/watch?v=5pr423z3sq4 join a support group learn more about breast cancer treatment by visiting www.knowyourbreastcancer.com or connect with a support group through the symphony sisterhood on facebook symphony sisterhood or knowyourbreastcancer.com physician education breast cancer publications client login ordering patient education breast cancer faqs insurance coverage client login united states international agendia about agendia investors & press accreditations & licenses career opportunities contact us 22 morgan irvine, ca 92618 888.321.2732 us: email science park 406 1098xh amsterdam, the netherlands +31 (0)20 462 1510 amsterdam: email     © 2018 agendia regulatory / license general terms of service general terms & conditions - agendia, nv notice of privacy practices privacy policy social media policy references you are about to access another agendia website with content about products only available in selected regions outside of the united states. in order to proceed, please confirm that you are a healthcare professional based outside of the united states and wish to continue. yes enter site no stay on agendia.com

URL analysis for mammaprint.co.uk


http://www.agendia.com/about/board-of-directors/
http://www.agendia.com/patient/breast/mailto:[email protected]
http://www.agendia.com/patients/
http://www.agendia.com/healthcare-professionals/educational-presentations/
http://www.agendia.com/patient/breast/mailto:[email protected]
http://www.agendia.com/investor-relations/
http://www.agendia.com/patient/breast/#inline-4
http://www.agendia.com/about/awards-and-recognition/
http://www.agendia.com/?p=255
http://www.agendia.com/patient/breast/#inline-5
http://www.agendia.com/agendia-news-and-press-releases/
http://www.agendia.com/media/low-risk-luminal-a-patient.pdf
http://www.agendia.com/our-science/
http://www.agendia.com/media/june2017_lr-luminal_a-summary-pages_patient.pdf
http://www.agendia.com/healthcare-professionals/

Whois Information


Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

Error for "mammaprint.co.uk".

the WHOIS query quota for 2600:3c03:0000:0000:f03c:91ff:feae:779d has been exceeded
and will be replenished in 223 seconds

WHOIS lookup made at 06:03:44 23-Jul-2017

--
This WHOIS information is provided for free by Nominet UK the central registry
for .uk domain names. This information and the .uk WHOIS are:

Copyright Nominet UK 1996 - 2017.

You may not access the .uk WHOIS or use any data from it except as permitted
by the terms of use available in full at http://www.nominet.uk/whoisterms,
which includes restrictions on: (A) use of the data for advertising, or its
repackaging, recompilation, redistribution or reuse (B) obscuring, removing
or hiding any or all of this notice and (C) exceeding query rate or volume
limits. The data is provided on an 'as-is' basis and may lag behind the
register. Access may be withdrawn or restricted at any time.

  REFERRER http://www.nominet.org.uk

  REGISTRAR Nominet UK

SERVERS

  SERVER co.uk.whois-servers.net

  ARGS mammaprint.co.uk

  PORT 43

  TYPE domain

DISCLAIMER
This WHOIS information is provided for free by Nominet UK the central registry
for .uk domain names. This information and the .uk WHOIS are:
Copyright Nominet UK 1996 - 2017.
You may not access the .uk WHOIS or use any data from it except as permitted
by the terms of use available in full at http://www.nominet.uk/whoisterms,
which includes restrictions on: (A) use of the data for advertising, or its
repackaging, recompilation, redistribution or reuse (B) obscuring, removing
or hiding any or all of this notice and (C) exceeding query rate or volume
limits. The data is provided on an 'as-is' basis and may lag behind the
register. Access may be withdrawn or restricted at any time.

  REGISTERED no

DOMAIN

  NAME mammaprint.co.uk

NSERVER

  NS2.THEPEOPLESVALLEY.NET 82.94.245.200

  NS1.THEPEOPLESVALLEY.NET 212.72.36.36

Go to top

Mistakes


The following list shows you to spelling mistakes possible of the internet users for the website searched .

  • www.umammaprint.com
  • www.7mammaprint.com
  • www.hmammaprint.com
  • www.kmammaprint.com
  • www.jmammaprint.com
  • www.imammaprint.com
  • www.8mammaprint.com
  • www.ymammaprint.com
  • www.mammaprintebc.com
  • www.mammaprintebc.com
  • www.mammaprint3bc.com
  • www.mammaprintwbc.com
  • www.mammaprintsbc.com
  • www.mammaprint#bc.com
  • www.mammaprintdbc.com
  • www.mammaprintfbc.com
  • www.mammaprint&bc.com
  • www.mammaprintrbc.com
  • www.urlw4ebc.com
  • www.mammaprint4bc.com
  • www.mammaprintc.com
  • www.mammaprintbc.com
  • www.mammaprintvc.com
  • www.mammaprintvbc.com
  • www.mammaprintvc.com
  • www.mammaprint c.com
  • www.mammaprint bc.com
  • www.mammaprint c.com
  • www.mammaprintgc.com
  • www.mammaprintgbc.com
  • www.mammaprintgc.com
  • www.mammaprintjc.com
  • www.mammaprintjbc.com
  • www.mammaprintjc.com
  • www.mammaprintnc.com
  • www.mammaprintnbc.com
  • www.mammaprintnc.com
  • www.mammaprinthc.com
  • www.mammaprinthbc.com
  • www.mammaprinthc.com
  • www.mammaprint.com
  • www.mammaprintc.com
  • www.mammaprintx.com
  • www.mammaprintxc.com
  • www.mammaprintx.com
  • www.mammaprintf.com
  • www.mammaprintfc.com
  • www.mammaprintf.com
  • www.mammaprintv.com
  • www.mammaprintvc.com
  • www.mammaprintv.com
  • www.mammaprintd.com
  • www.mammaprintdc.com
  • www.mammaprintd.com
  • www.mammaprintcb.com
  • www.mammaprintcom
  • www.mammaprint..com
  • www.mammaprint/com
  • www.mammaprint/.com
  • www.mammaprint./com
  • www.mammaprintncom
  • www.mammaprintn.com
  • www.mammaprint.ncom
  • www.mammaprint;com
  • www.mammaprint;.com
  • www.mammaprint.;com
  • www.mammaprintlcom
  • www.mammaprintl.com
  • www.mammaprint.lcom
  • www.mammaprint com
  • www.mammaprint .com
  • www.mammaprint. com
  • www.mammaprint,com
  • www.mammaprint,.com
  • www.mammaprint.,com
  • www.mammaprintmcom
  • www.mammaprintm.com
  • www.mammaprint.mcom
  • www.mammaprint.ccom
  • www.mammaprint.om
  • www.mammaprint.ccom
  • www.mammaprint.xom
  • www.mammaprint.xcom
  • www.mammaprint.cxom
  • www.mammaprint.fom
  • www.mammaprint.fcom
  • www.mammaprint.cfom
  • www.mammaprint.vom
  • www.mammaprint.vcom
  • www.mammaprint.cvom
  • www.mammaprint.dom
  • www.mammaprint.dcom
  • www.mammaprint.cdom
  • www.mammaprintc.om
  • www.mammaprint.cm
  • www.mammaprint.coom
  • www.mammaprint.cpm
  • www.mammaprint.cpom
  • www.mammaprint.copm
  • www.mammaprint.cim
  • www.mammaprint.ciom
  • www.mammaprint.coim
  • www.mammaprint.ckm
  • www.mammaprint.ckom
  • www.mammaprint.cokm
  • www.mammaprint.clm
  • www.mammaprint.clom
  • www.mammaprint.colm
  • www.mammaprint.c0m
  • www.mammaprint.c0om
  • www.mammaprint.co0m
  • www.mammaprint.c:m
  • www.mammaprint.c:om
  • www.mammaprint.co:m
  • www.mammaprint.c9m
  • www.mammaprint.c9om
  • www.mammaprint.co9m
  • www.mammaprint.ocm
  • www.mammaprint.co
  • mammaprint.co.ukm
  • www.mammaprint.con
  • www.mammaprint.conm
  • mammaprint.co.ukn
  • www.mammaprint.col
  • www.mammaprint.colm
  • mammaprint.co.ukl
  • www.mammaprint.co
  • www.mammaprint.co m
  • mammaprint.co.uk
  • www.mammaprint.cok
  • www.mammaprint.cokm
  • mammaprint.co.ukk
  • www.mammaprint.co,
  • www.mammaprint.co,m
  • mammaprint.co.uk,
  • www.mammaprint.coj
  • www.mammaprint.cojm
  • mammaprint.co.ukj
  • www.mammaprint.cmo
Show All Mistakes Hide All Mistakes